AR075243A1 - Derivados del 1-fenil-2-piridinil alquil alcohol como inhibidores de fosfodiesterasa - Google Patents

Derivados del 1-fenil-2-piridinil alquil alcohol como inhibidores de fosfodiesterasa

Info

Publication number
AR075243A1
AR075243A1 ARP100100311A ARP100100311A AR075243A1 AR 075243 A1 AR075243 A1 AR 075243A1 AR P100100311 A ARP100100311 A AR P100100311A AR P100100311 A ARP100100311 A AR P100100311A AR 075243 A1 AR075243 A1 AR 075243A1
Authority
AR
Argentina
Prior art keywords
phenyl
derivatives
branched
linear
optionally substituted
Prior art date
Application number
ARP100100311A
Other languages
English (en)
Inventor
Gabriele Amari
Elisabetta Armani
Maurizio Delcanale
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40674203&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR075243(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of AR075243A1 publication Critical patent/AR075243A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • A61M15/0065Inhalators with dosage or measuring devices
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10Preparation of respiratory gases or vapours
    • A61M16/14Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Inhibidores de la enzima fosfodiesterasa 4 (PDE4). Más particularmente se relaciona con derivados de 1-fenil-2-piridinil alquil alcohol, con procesos para la preparacion de los mismos, con composiciones que los comprenden, combinaciones y usos terapéuticos de los mismos. Reivindicacion 1: Un compuesto caracterizado porque es de formula general (1) como (-) enantiomero n es 0 o 1; R1 y R2 pueden ser iguales o diferentes, y se seleccionan del grupo que consiste en alquilo C1-6 lineal o ramificado, opcionalmente sustituido con uno o más átomos de halogeno; OR3 en donde R3 es un alquilo C1-6 lineal o ramificado opcionalmente sustituido con uno o más átomos de halogeno o grupos cicloalquilo C3-7; y HNSO2R4 en donde R4 es un alquilo C1-4 lineal o ramificado opcionalmente sustituido con uno o más átomos de halogeno, en donde al menos uno de R1 y R2 es HNSO2R4, las sales orgánicas o inorgánicas farmacéuticamente aceptables, hidratos, solvatos o complejos de adicion de los mismos. Reivindicacion 9: Un compuesto de formula general (2) caracterizado porque n es como se definio en la reivindicacion 1 y el átomo de carbono que se representa con un asterisco abajo muestra una configuracion (S).
ARP100100311A 2009-02-06 2010-02-04 Derivados del 1-fenil-2-piridinil alquil alcohol como inhibidores de fosfodiesterasa AR075243A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09001660A EP2216327A1 (en) 2009-02-06 2009-02-06 Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
AR075243A1 true AR075243A1 (es) 2011-03-16

Family

ID=40674203

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100311A AR075243A1 (es) 2009-02-06 2010-02-04 Derivados del 1-fenil-2-piridinil alquil alcohol como inhibidores de fosfodiesterasa

Country Status (33)

Country Link
US (5) US8440834B2 (es)
EP (2) EP2216327A1 (es)
JP (2) JP5612610B2 (es)
KR (1) KR101337728B1 (es)
CN (1) CN102317262B (es)
AR (1) AR075243A1 (es)
AU (1) AU2010211274B2 (es)
BR (1) BRPI1005695A8 (es)
CA (1) CA2751494C (es)
CL (1) CL2011001876A1 (es)
CO (1) CO6400217A2 (es)
CY (1) CY1113764T1 (es)
EA (1) EA019113B1 (es)
ES (1) ES2395528T3 (es)
GE (1) GEP20135919B (es)
HR (1) HRP20121004T1 (es)
IL (1) IL214446A (es)
JO (1) JO2761B1 (es)
MA (1) MA33105B1 (es)
ME (1) ME02325B (es)
MX (1) MX2011007857A (es)
MY (1) MY152048A (es)
NZ (1) NZ594413A (es)
PE (1) PE20120055A1 (es)
PL (1) PL2393782T3 (es)
PT (1) PT2393782E (es)
RS (1) RS52605B (es)
SG (1) SG173208A1 (es)
SI (1) SI2393782T1 (es)
TN (1) TN2011000346A1 (es)
TW (1) TWI459945B (es)
UA (1) UA102574C2 (es)
WO (1) WO2010089107A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2216327A1 (en) 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
NO2600830T3 (es) 2010-08-03 2018-07-21
KR101803121B1 (ko) * 2010-08-03 2017-11-29 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제를 포함하는 약학적 제제
WO2012168226A1 (en) * 2011-06-06 2012-12-13 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
EP2760838B1 (en) 2011-09-26 2017-05-10 Chiesi Farmaceutici S.p.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
BR112014009471A2 (pt) 2011-10-21 2017-04-18 Chiesi Farm Spa compostos, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit
WO2013087749A1 (en) * 2011-12-16 2013-06-20 Chiesi Farmaceutici S.P.A. Potentiation induced by pde4 inhibitors in the treatment of leukemia
IN2014DN10239A (es) * 2012-06-04 2015-08-07 Chiesi Farma Spa
KR20150092173A (ko) * 2012-12-05 2015-08-12 키에시 파르마슈티시 엣스. 피. 에이. Pde4-억제제로서 페닐에틸피리딘 유도체
CN104822669A (zh) 2012-12-05 2015-08-05 奇斯药制品公司 作为pde-4抑制剂的苯基乙基吡啶衍生物
EP2928869B1 (en) * 2012-12-05 2019-02-20 Chiesi Farmaceutici S.p.A. 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors
CA2893622A1 (en) 2012-12-05 2014-06-12 Chiesi Farmaceutici S.P.A. Novel compounds
US9427376B2 (en) 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
RS61558B1 (sr) 2013-10-22 2021-04-29 Chiesi Farm Spa Kristalni oblik pde4 inhibitora
US9145409B2 (en) 2013-12-05 2015-09-29 Chiesi Farmaceutici S.P.A Benzhydryl derivatives
HK1225385A1 (zh) 2013-12-05 2017-09-08 奇斯药制品公司 用於治疗呼吸病的杂芳基衍生物
EP3152202B1 (en) * 2014-06-04 2018-11-28 Chiesi Farmaceutici S.p.A. 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)--2-carbonyloxy)ethyl)pyridine derivatives as pde-4 inhibitors and muscarinic m3 receptor antagonists
EP3152203A1 (en) * 2014-06-04 2017-04-12 Chiesi Farmaceutici S.p.A. 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)- 2-carbonyloxy)ethyl)pyridine derivatives as pde-4 inhibitors
US9763924B2 (en) * 2014-06-05 2017-09-19 Chiesi Farmaceutici S.P.A. Aminoester derivatives
US9326976B2 (en) * 2014-06-05 2016-05-03 Chiesi Farmaceutici S.P.A. Carbamate derivatives
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
EP3487501A1 (en) * 2016-07-20 2019-05-29 Allergan, Inc. Methods, compositions, and compounds for treatment of dermatological and ocular conditions
MA51413A (fr) * 2017-12-28 2021-04-28 Chiesi Farm Spa Utilisation de dérivés d'alcool alkylique de 1-phényl-2-pyridinyl pour le traitement de la fibrose kystique
BR112021001402A2 (pt) 2018-07-27 2021-04-27 Chiesi Farmaceutici S.P.A. novas partículas carreadoras para formulações de pó seco para inalação
CN115466169B (zh) * 2021-06-10 2024-03-26 中国医学科学院药物研究所 取代邻苯二酚醚类化合物及其制备方法和应用
CN118475343A (zh) 2021-12-21 2024-08-09 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂
WO2023208982A1 (en) 2022-04-27 2023-11-02 Chiesi Farmaceutici S.P.A. Crystal form of a pde4 inhibitor
WO2024027901A1 (en) 2022-08-02 2024-02-08 Chiesi Farmaceutici S.P.A. Predictive biomarker of clinical response to a pde4 inhibitor
CA3268102A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. CAPSULE INHALATOR FOR THE ADMINISTRATION OF A PHOSPHODIESTERASE-4 INHIBITOR
KR20250069949A (ko) 2022-09-22 2025-05-20 키에시 파르마슈티시 엣스. 피. 에이. 포스포다이에스테라제-4 억제제의 투여를 위한 캡슐 흡입기
CA3268243A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. CAPSULE INHALATOR FOR THE ADMINISTRATION OF A PHOSPHODIESTERASE-4 INHIBITOR
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy
WO2025149100A2 (zh) * 2025-04-29 2025-07-17 北京泰德制药股份有限公司 含有pde4抑制剂化合物a的药物组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW263495B (es) * 1992-12-23 1995-11-21 Celltech Ltd
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
CN1046939C (zh) * 1993-07-02 1999-12-01 比克·古尔顿·劳姆贝尔格化学公司 氟烷氧基取代的苯甲酰胺类及其制备方法和应用
GB9412573D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
EP2044023B1 (en) 2006-07-14 2011-01-19 CHIESI FARMACEUTICI S.p.A. Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors
EP2022783A1 (en) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2070913A1 (en) 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Ester derivatives as phosphodiesterase inhibitors
EP2110375A1 (en) 2008-04-14 2009-10-21 CHIESI FARMACEUTICI S.p.A. Phosphodiesterase-4 inhibitors belonging to the tertiary amine class
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
NO2600830T3 (es) 2010-08-03 2018-07-21
KR101803121B1 (ko) 2010-08-03 2017-11-29 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제를 포함하는 약학적 제제
WO2012168226A1 (en) 2011-06-06 2012-12-13 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
EP2760838B1 (en) 2011-09-26 2017-05-10 Chiesi Farmaceutici S.p.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
BR112014009471A2 (pt) 2011-10-21 2017-04-18 Chiesi Farm Spa compostos, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit
IN2014DN10239A (es) 2012-06-04 2015-08-07 Chiesi Farma Spa
EP2928869B1 (en) 2012-12-05 2019-02-20 Chiesi Farmaceutici S.p.A. 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors

Also Published As

Publication number Publication date
MA33105B1 (fr) 2012-03-01
US20130012487A1 (en) 2013-01-10
CA2751494C (en) 2017-03-07
TN2011000346A1 (en) 2013-03-27
PE20120055A1 (es) 2012-02-16
ES2395528T3 (es) 2013-02-13
RS52605B (sr) 2013-04-30
EP2216327A1 (en) 2010-08-11
TWI459945B (zh) 2014-11-11
JP2015038079A (ja) 2015-02-26
EP2393782A1 (en) 2011-12-14
JP5612610B2 (ja) 2014-10-22
PL2393782T3 (pl) 2013-02-28
US20140179647A1 (en) 2014-06-26
MY152048A (en) 2014-08-15
ME02325B (me) 2016-06-20
BRPI1005695A2 (pt) 2017-06-06
US8859778B2 (en) 2014-10-14
CO6400217A2 (es) 2012-03-15
WO2010089107A1 (en) 2010-08-12
CL2011001876A1 (es) 2011-10-28
JP2012516863A (ja) 2012-07-26
US20130289010A1 (en) 2013-10-31
CA2751494A1 (en) 2010-08-12
AU2010211274A1 (en) 2011-08-25
IL214446A (en) 2014-12-31
AU2010211274B2 (en) 2016-03-17
EA201190099A1 (ru) 2012-02-28
US20100204256A1 (en) 2010-08-12
CY1113764T1 (el) 2016-07-27
SG173208A1 (en) 2011-09-29
US8440834B2 (en) 2013-05-14
CN102317262B (zh) 2014-08-06
EP2393782B1 (en) 2012-09-12
US9056176B2 (en) 2015-06-16
NZ594413A (en) 2013-05-31
SI2393782T1 (sl) 2013-01-31
US20140378423A1 (en) 2014-12-25
KR20110094356A (ko) 2011-08-23
HK1162508A1 (en) 2012-08-31
US8648204B2 (en) 2014-02-11
EA019113B1 (ru) 2014-01-30
GEP20135919B (en) 2013-09-10
BRPI1005695A8 (pt) 2017-12-26
MX2011007857A (es) 2011-08-15
KR101337728B1 (ko) 2013-12-09
UA102574C2 (ru) 2013-07-25
JO2761B1 (en) 2014-03-15
TW201032804A (en) 2010-09-16
CN102317262A (zh) 2012-01-11
IL214446A0 (en) 2011-09-27
HRP20121004T1 (hr) 2012-12-31
PT2393782E (pt) 2012-12-26

Similar Documents

Publication Publication Date Title
AR075243A1 (es) Derivados del 1-fenil-2-piridinil alquil alcohol como inhibidores de fosfodiesterasa
CO6290658A2 (es) Derivados de azetidina y ciclobutano como inhibidores de jack
NI201200191A (es) Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
PE20130010A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina como inhibidor de la integrasa del vih
AR080802A1 (es) Compuestos de complejos de fe (iii) para el tratamiento y la profilaxis de los sintomas de deficiencia de hierro y anemias por deficiencia de hierro
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
PY1153144A (es) Inhibidores macrocíclicos de virus flaviviridae
PE20141193A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
ECSP12011684A (es) Inhibidores de los virus flaviviridae.
UY33226A (es) Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
CU24272B1 (es) Derivados de tetrahidropirido-pirimidina como inhibidores de mek
CO6280509A2 (es) Derivados de carboxamidas azabiciclicas su preparacion y su aplicacion en terapeutica
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
AR081628A1 (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
AR089774A1 (es) Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
UY32848A (es) Compuestos heterocíclicos de oxima
UY32630A (es) Derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos, su preparación y su aplicación en terapéutica.
EA201201052A1 (ru) Замещенные нафтиридины и их применение в качестве ингибиторов киназы syk
AR075332A1 (es) Dionas ciclicas como herbicidas
CO6150181A2 (es) Compuesto 6-(bencilo sustituido con heterociclo)-4-oxoquinolina y su uso como inhibidor de integrasa vih
AR072518A1 (es) Derivados de imidazo [1,2-a]piridina, su procedimiento de preparacion, composiciones farmaceuticas y su utilizacion particularmente como inhibidores de met."
PE20160934A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolisis
ECSP088963A (es) Aminopirazolopiridinas sustituidas y sus sales, sus preparaciones y composiciones farmacéuticas que las comprenden

Legal Events

Date Code Title Description
FC Refusal